Prognostic value of 18F-FDG PET/CT in patients with advanced or metastatic non-small-cell lung cancer treated with immune checkpoint inhibitors: A systematic review and meta-analysis
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Prognostic value of 18F-FDG PET/CT in patients with advanced or metastatic non-small-cell lung cancer treated with immune checkpoint inhibitors: A systematic review and meta-analysis
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 13, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2022-11-17
DOI
10.3389/fimmu.2022.1014063
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Prognostic value of total tumour volume, adding necrosis to metabolic tumour volume, in advanced or metastatic non-small cell lung cancer treated with first-line pembrolizumab
- (2022) Florian Eude et al. ANNALS OF NUCLEAR MEDICINE
- The value of the Standardized Uptake Value (SUV) and Metabolic Tumor Volume (MTV) in lung cancer
- (2022) Rodney J. Hicks SEMINARS IN NUCLEAR MEDICINE
- Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer
- (2021) Hossein Borghaei et al. JOURNAL OF CLINICAL ONCOLOGY
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- PD-L1 as a biomarker of response to immune-checkpoint inhibitors
- (2021) Deborah Blythe Doroshow et al. Nature Reviews Clinical Oncology
- Quantitative FDG PET Assessment for Oncology Therapy
- (2021) Kenji Hirata et al. Cancers
- The Value of 18F-FDG PET/CT in Predicting the Response to PD-1 Blocking Immunotherapy in Advanced NSCLC Patients with High-Level PD-L1 Expression
- (2021) Karolien Vekens et al. Clinical Lung Cancer
- Impact of Antibiotic Therapy and Metabolic Parameters in Non-Small Cell Lung Cancer Patients Receiving Checkpoint Inhibitors
- (2021) Angelo Castello et al. Journal of Clinical Medicine
- Prognostic significance of volume-based 18F-FDG PET/CT parameters and correlation with PD-L1 expression in patients with surgically resected lung adenocarcinoma
- (2021) Dalong Wang et al. MEDICINE
- Correlation of epidermal growth factor receptor mutation status and PD-L1 expression with [18F]FDG PET using volume-based parameters in non-small cell lung cancer
- (2021) Mariko Ishimura et al. NUCLEAR MEDICINE COMMUNICATIONS
- First-Line Pembrolizumab Mono- or Combination Therapy of Non-Small Cell Lung Cancer: Baseline Metabolic Biomarkers Predict Outcomes
- (2021) David Lang et al. Cancers
- Circulating Tumor Cells and Metabolic Parameters in NSCLC Patients Treated with Checkpoint Inhibitors
- (2020) Angelo Castello et al. Cancers
- Potential of FDG-PET as Prognostic Significance after anti-PD-1 Antibody against Patients with Previously Treated Non-Small Cell Lung Cancer
- (2020) Kosuke Hashimoto et al. Journal of Clinical Medicine
- 18F-FDG Pet Parameters and Radiomics Features Analysis in Advanced Nsclc Treated with Immunotherapy as Predictors of Therapy Response and Survival
- (2020) Giulia Polverari et al. Cancers
- Positron Emission Tomography-Based Response to Target and Immunotherapies in Oncology
- (2020) Maria Isabella Donegani et al. Medicina-Lithuania
- Baseline metabolic tumor volume as a strong predictive and prognostic biomarker in patients with non-small cell lung cancer treated with PD1 inhibitors: a prospective study
- (2020) David Chardin et al. Journal for ImmunoTherapy of Cancer
- Association of the Metabolic Score Using Baseline FDG-PET/CT and dNLR with Immunotherapy Outcomes in Advanced NSCLC Patients Treated with First-Line Pembrolizumab
- (2020) Romain-David Seban et al. Cancers
- FDG-PET biomarkers associated with long-term benefit from first-line immunotherapy in patients with advanced non-small cell lung cancer
- (2020) Romain-David Seban et al. ANNALS OF NUCLEAR MEDICINE
- Pseudoprogression and hyperprogression in lung cancer: a comprehensive review of literature
- (2020) Laiyan Zhou et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy
- (2020) Yang Gao et al. NATURE CELL BIOLOGY
- Tumor metabolic volume by 18F-FDG-PET as a prognostic predictor of first-line pembrolizumab for NSCLC patients with PD-L1 ≥ 50%
- (2020) Ou Yamaguchi et al. Scientific Reports
- Baseline PET features to predict prognosis in primary mediastinal B cell lymphoma: a comparative analysis of different methods for measuring baseline metabolic tumour volume
- (2019) Luca Ceriani et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- 18F-FDG PET/CT in non-small-cell lung cancer patients
- (2019) Laura Evangelista et al. NUCLEAR MEDICINE COMMUNICATIONS
- 18F-FDG PET metabolic-to-morphological volume ratio predicts PD-L1 tumour expression and response to PD-1 blockade in non-small-cell lung cancer
- (2019) Mario Jreige et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- New insight on the correlation of metabolic status on 18F-FDG PET/CT with immune marker expression in patients with non-small cell lung cancer
- (2019) Yang Wang et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment
- (2019) Narjust Duma et al. MAYO CLINIC PROCEEDINGS
- Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
- (2019) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors
- (2019) Romain-David Seban et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Significance of Glucose Transporter Type 1 (GLUT-1) Expression in the Therapeutic Strategy for Pancreatic Ductal Adenocarcinoma
- (2018) Hiroshi Kurahara et al. ANNALS OF SURGICAL ONCOLOGY
- Prognostic Value of Pretreatment FDG-PET Parameters in High-dose Image-guided Radiotherapy for Oligometastatic Non–Small-cell Lung Cancer
- (2018) Alexander L. Chin et al. Clinical Lung Cancer
- Role of Various Metabolic Parameters Derived From Baseline 18F-FDG PET/CT as Prognostic Markers in Non–Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy
- (2018) Akshima Sharma et al. CLINICAL NUCLEAR MEDICINE
- Defining the role of the tumor vasculature in antitumor immunity and immunotherapy
- (2018) Marco B. Schaaf et al. Cell Death & Disease
- Treatment of Advanced Non–Small Cell Lung Cancer in 2018
- (2018) Deborah B. Doroshow et al. JAMA Oncology
- Why harmonization is needed when using FDG PET/CT as a prognosticator: demonstration with EARL-compliant SUV as an independent prognostic factor in lung cancer
- (2018) Benjamin Houdu et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
- (2018) T A Chan et al. ANNALS OF ONCOLOGY
- Increased CD3+ T cells with a low FOXP3+/CD8+ T cell ratio can predict anti-PD-1 therapeutic response in non-small cell lung cancer patients
- (2018) Hyojin Kim et al. MODERN PATHOLOGY
- Cell death and immunity in cancer: From danger signals to mimicry of pathogen defense responses
- (2017) Abhishek D. Garg et al. IMMUNOLOGICAL REVIEWS
- Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study
- (2017) Patrick A. Ott et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review
- (2017) Robert Brody et al. LUNG CANCER
- Metabolic characteristics of programmed cell death-ligand 1-expressing lung cancer on 18 F-fluorodeoxyglucose positron emission tomography/computed tomography
- (2017) Kazuki Takada et al. Cancer Medicine
- Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery
- (2016) Egesta Lopci et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
- (2016) Louis Fehrenbacher et al. LANCET
- Metabolic tumor burden as marker of outcome in advanced EGFR wild-type NSCLC patients treated with erlotinib
- (2016) Anne Winther-Larsen et al. LUNG CANCER
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Control of PD-L1 Expression by Oncogenic Activation of the AKT–mTOR Pathway in Non–Small Cell Lung Cancer
- (2015) Kristin J. Lastwika et al. CANCER RESEARCH
- Prognostic Role of Tumor-Infiltrating Lymphocytes in Lung Cancer: a Meta-Analysis
- (2015) Yiting Geng et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Prognostic value of volumetric parameters of 18F-FDG PET in non-small-cell lung cancer: a meta-analysis
- (2014) Hyung-Jun Im et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Hypoxia-inducible factors in regulation of immune responses in tumour microenvironment
- (2014) Vinit Kumar et al. IMMUNOLOGY
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Necrosis and apoptotic index as prognostic factors in non-small cell lung carcinoma: a review
- (2014) Charalampos Gkogkou et al. SpringerPlus
- Prognostic Value of the Quantitative Metabolic Volumetric Measurement on 18F-FDG PET/CT in Stage IV Nonsurgical Small-cell Lung Cancer
- (2011) Shengri Liao et al. ACADEMIC RADIOLOGY
- Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer
- (2011) Shengri Liao et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells
- (2011) Andrea Facciabene et al. NATURE
- Assessment of factors influencing FDG uptake in non-small cell lung cancer on PET/CT by investigating histological differences in expression of glucose transporters 1 and 3 and tumour size
- (2010) Naohisa Suzawa et al. LUNG CANCER
- Prognostic Value of Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography Imaging in Patients With Advanced-Stage Non–Small-Cell Lung Carcinoma
- (2008) Jenny K. Hoang et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now